SELLAS Life Sciences Group (NASDAQ:SLS) Trading 9.3% Higher – What’s Next?

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) shares traded up 9.3% during mid-day trading on Friday . The company traded as high as $5.50 and last traded at $5.4970. 2,028,063 shares traded hands during mid-day trading, a decline of 76% from the average session volume of 8,385,827 shares. The stock had previously closed at $5.03.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a report on Thursday, January 22nd. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, SELLAS Life Sciences Group presently has an average rating of “Hold” and a consensus target price of $7.00.

SELLAS Life Sciences Group Stock Up 8.2%

The firm has a fifty day moving average of $4.33 and a 200-day moving average of $2.76. The stock has a market capitalization of $774.87 million, a price-to-earnings ratio of -19.41 and a beta of 2.18.

Institutional Investors Weigh In On SELLAS Life Sciences Group

Institutional investors and hedge funds have recently made changes to their positions in the business. Larson Financial Group LLC purchased a new position in SELLAS Life Sciences Group during the 4th quarter valued at about $26,000. Beacon Pointe Advisors LLC purchased a new stake in shares of SELLAS Life Sciences Group in the fourth quarter valued at about $38,000. Concurrent Investment Advisors LLC acquired a new stake in shares of SELLAS Life Sciences Group in the fourth quarter valued at approximately $38,000. Money Concepts Capital Corp acquired a new stake in shares of SELLAS Life Sciences Group in the fourth quarter valued at approximately $40,000. Finally, CWM LLC increased its stake in shares of SELLAS Life Sciences Group by 124.7% during the 4th quarter. CWM LLC now owns 11,782 shares of the company’s stock worth $44,000 after purchasing an additional 6,538 shares in the last quarter. 17.38% of the stock is currently owned by hedge funds and other institutional investors.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.